Northstar Advisory Group LLC Grows Stake in Eli Lilly and Company $LLY

Northstar Advisory Group LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 383.5% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,113 shares of the company’s stock after acquiring an additional 1,676 shares during the period. Northstar Advisory Group LLC’s holdings in Eli Lilly and Company were worth $1,612,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of LLY. Sumitomo Mitsui Financial Group Inc. bought a new stake in Eli Lilly and Company in the 2nd quarter valued at about $27,000. Evolution Wealth Management Inc. bought a new position in Eli Lilly and Company in the 2nd quarter valued at $29,000. Steph & Co. boosted its stake in Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after buying an additional 29 shares during the period. Financial Gravity Companies Inc. purchased a new position in shares of Eli Lilly and Company during the second quarter worth about $31,000. Finally, Bare Financial Services Inc grew its stake in Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after buying an additional 29 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.1%

Shares of Eli Lilly and Company stock opened at $1,063.34 on Tuesday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The company’s 50 day moving average is $1,057.99 and its 200 day moving average is $883.36. The company has a market cap of $1.01 trillion, a price-to-earnings ratio of 52.02, a price-to-earnings-growth ratio of 0.80 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company’s revenue was up 53.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on LLY. National Bankshares set a $1,286.00 price objective on shares of Eli Lilly and Company in a research note on Monday, December 1st. Jefferies Financial Group lifted their price objective on Eli Lilly and Company from $976.00 to $1,300.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Wednesday, January 14th. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Finally, Wolfe Research upped their price target on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. Four equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Buy” and a consensus target price of $1,174.61.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.